EP3848365A4 - TRK INHIBITORS AS AN ANTI-CANCER AGENT - Google Patents

TRK INHIBITORS AS AN ANTI-CANCER AGENT Download PDF

Info

Publication number: EP3848365A4
Authority: EP; European Patent Office
Prior art keywords: cancer agent; trk inhibitors; trk; inhibitors; cancer
Prior art date: 2018-09-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

EP19858588.7A

Other languages

German (de)

French (fr)

Other versions

EP3848365A1 (en

Inventor

Boyu Zhong

Tony Yantao Zhang

Yiju CAO

Guangming Chen

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Tyligand Bioscience Shanghai Ltd

Original Assignee

Tyligand Bioscience Shanghai Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-09-03

Filing date

2019-09-03

Publication date

2022-06-01

2019-09-03 Application filed by Tyligand Bioscience Shanghai Ltd filed Critical Tyligand Bioscience Shanghai Ltd

2021-07-14 Publication of EP3848365A1 publication Critical patent/EP3848365A1/en

2022-06-01 Publication of EP3848365A4 publication Critical patent/EP3848365A4/en

Status Pending legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/06—Peri-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EP19858588.7A 2018-09-03 2019-09-03 TRK INHIBITORS AS AN ANTI-CANCER AGENT Pending EP3848365A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
CN201811019556		2018-09-03
PCT/CN2019/104218 WO2020048455A1 (en)	2018-09-03	2019-09-03	Trk inhibitor as anti-cancer drug

Publications (2)

Publication Number	Publication Date
EP3848365A1 EP3848365A1 (en)	2021-07-14
EP3848365A4 true EP3848365A4 (en)	2022-06-01

Family

ID=69721561

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP19858588.7A Pending EP3848365A4 (en)	2018-09-03	2019-09-03	TRK INHIBITORS AS AN ANTI-CANCER AGENT

Country Status (9)

Country	Link
US (1)	US11952364B2 (en)
EP (1)	EP3848365A4 (en)
JP (1)	JP7443373B2 (en)
KR (1)	KR102842021B1 (en)
CN (1)	CN112739691B (en)
AU (1)	AU2019335450C1 (en)
BR (1)	BR112021004003A2 (en)
CA (1)	CA3111105A1 (en)
WO (1)	WO2020048455A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN113121432A (en) *	2021-04-16	2021-07-16	南京工业大学	Synthesis method of aliphatic alkene with guide group
WO2023062575A1 (en) *	2021-10-14	2023-04-20	Ideaya Biosciences, Inc.	Cyclic vinyl sulfone compounds as wrn inhibitors
WO2025040141A1 (en) *	2023-08-23	2025-02-27	Shenzhen Newdel Biotech Co., Ltd.	Use of compound 1 in treating or preventing disease associated with c-kit mutation or c-kit fusion mutation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ561526A (en)	2005-02-16	2010-11-26	Astrazeneca Ab	Pyrazole derivatives as Trk kinase inhibitors
WO2006115452A1 (en)	2005-04-27	2006-11-02	Astrazeneca Ab	Use of pyrazolyl-pyrimidine derivatives in the treatment of pain
CA2667962A1 (en)	2006-10-30	2008-05-08	Novartis Ag	Heterocyclic compounds as antiinflammatory agents
WO2009136663A1 (en)	2008-05-08	2009-11-12	Takeda Pharmaceutical Company Limited	Fused heterocyclic derivatives and use thereof
TWI365185B (en)	2008-07-24	2012-06-01	Lilly Co Eli	Amidophenoxyindazoles useful as inhibitors of c-met
CN103965200B (en)	2008-09-22	2016-06-08	阵列生物制药公司	As imidazo [1,2-B] pyridazine compound of the replacement of TRK kinase inhibitor
CN102264736B (en)	2008-10-22	2013-08-14	阵列生物制药公司	Substituted pyrazolo[1,5-a]pyrimidine compounds as TRK kinase inhibitors
JP2017532344A (en)	2014-10-14	2017-11-02	デシファラファーマスーティカルズ，エルエルシー	TRK kinase-mediated inhibition of tumor growth and disease progression
WO2016089760A1 (en)	2014-12-02	2016-06-09	Ignyta, Inc.	Combinations for the treatment of neuroblastoma
TW201716085A (en) *	2015-08-12	2017-05-16	應克隆公司	Combination therapy for cancer
AU2016344058A1 (en)	2015-10-26	2018-05-17	Array Biopharma Inc.	Point mutations in Trk inhibitor-resistant cancer and methods relating to the same
CN106649345A (en)	2015-10-30	2017-05-10	微软技术许可有限责任公司	Automatic session creator for news
EP3442573A1 (en) *	2016-04-15	2019-02-20	Eli Lilly and Company	Combination of ramucirumab and merestinib for use in treatment of colorectal cancer
WO2018022438A1 (en) *	2016-07-29	2018-02-01	Eli Lilly And Company	Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer
ES2866348T3 (en) *	2016-11-16	2021-10-19	Lilly Co Eli	Combination therapy for cancer with exon 14 skipping mutation (s) or exon 14 skipping phenotype

2019
- 2019-09-03 CN CN201980057263.7A patent/CN112739691B/en active Active
- 2019-09-03 EP EP19858588.7A patent/EP3848365A4/en active Pending
- 2019-09-03 US US17/273,046 patent/US11952364B2/en active Active
- 2019-09-03 CA CA3111105A patent/CA3111105A1/en active Pending
- 2019-09-03 BR BR112021004003-0A patent/BR112021004003A2/en unknown
- 2019-09-03 KR KR1020217009459A patent/KR102842021B1/en active Active
- 2019-09-03 JP JP2021536140A patent/JP7443373B2/en active Active
- 2019-09-03 WO PCT/CN2019/104218 patent/WO2020048455A1/en not_active Ceased
- 2019-09-03 AU AU2019335450A patent/AU2019335450C1/en active Active

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
No further relevant documents disclosed *

Also Published As

Publication number	Publication date
KR20210054548A (en)	2021-05-13
JP2021536503A (en)	2021-12-27
US11952364B2 (en)	2024-04-09
CN112739691B (en)	2023-05-23
US20220388983A1 (en)	2022-12-08
CN112739691A (en)	2021-04-30
KR102842021B1 (en)	2025-08-05
AU2019335450A1 (en)	2021-05-06
WO2020048455A1 (en)	2020-03-12
BR112021004003A2 (en)	2021-05-25
AU2019335450C1 (en)	2025-05-29
JP7443373B2 (en)	2024-03-05
EP3848365A1 (en)	2021-07-14
CA3111105A1 (en)	2020-03-12
AU2019335450B2 (en)	2024-11-14

Publication	Publication Date	Title
EP3898616C0 (en)	2024-10-02	HETEROARYLAMIDES USABLE AS KIF18A INHIBITORS
EP3898592C0 (en)	2024-10-09	HETEROARYLAMIDES USABLE AS KIF18A INHIBITORS
EP3694846C0 (en)	2024-05-08	1-BENZYL-2-IMINO-4-PHENYL-5-OXOIMIDAZOLIDINE DERIVATIVES AS HIV PROTEASE INHIBITORS
MA54543A (en)	2022-03-30	KIF18A INHIBITORS
MA54550A (en)	2022-03-30	KIF18A INHIBITORS
EP3558969C0 (en)	2024-09-18	PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS
EP3541932A4 (en)	2021-03-03	CRISPR-CAS9 INHIBITORS
ME03485B (en)	2020-01-20	BENZIMIDAZOLE DERIVATIVES AS FLOMDOMAIN inhibitors
HUE056634T2 (en)	2022-02-28	Substituted carbonucleoside derivatives are useful as anti-cancer agents
EP3866927A4 (en)	2022-07-27	INDANDERIVATES AS HYPOXIA-INDUCABLE FACTOR 2 (ALPHA) INHIBITORS
IL304348A (en)	2023-09-01	cd73 inhibitors
LT3768674T (en)	2024-04-25	AMINOPYRIMIDINE DERIVATIVES AS CTPS1 INHIBITORS
MA52812A (en)	2021-04-14	SARM1 INHIBITORS
EP3768671C0 (en)	2024-05-22	SUBSTITUTED IMIDAZOLIDINI-2-ONE DERIVATIVES AS PRMT5 INHIBITORS
EP3483158A4 (en)	2020-07-29	HETEROCYCLIC COMPOUND AS FGRF4 INHIBITOR
EP3600313A4 (en)	2020-09-23	PIPERIDINE AS COVALENT MENIN INHIBITORS
EP3684772C0 (en)	2023-12-06	CYCLIC IMINOPYRIMIDINE DERIVATIVES AS KINASE INHIBITORS
MA52809A (en)	2021-04-14	SARM1 INHIBITORS
MA52813A (en)	2021-04-14	SARM1 INHIBITORS
ME03414B (en)	2020-01-20	IMIDAZOPYRAZOLONE AS PDE1 INHIBITORS
EP3822276A4 (en)	2022-04-06	HETEROCYCLIC COMPOUND AS TRK INHIBITOR
EP3817736A4 (en)	2021-07-28	PIKFYVE INHIBITORS
EP3749646A4 (en)	2020-12-23	HETEROARYL COMPOUNDS AS KINASE INHIBITORS
DK3458460T3 (en)	2021-03-01	IMIDAZOLES AS HISTONDEMETHYLASE INHIBITORS
EP4021438A4 (en)	2023-09-13	PATENTIFLORIN-A ANALOGAS AS VIRUCIDES

Legal Events

Date	Code	Title	Description
2020-03-14	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2021-06-11	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2021-06-11	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2021-07-14	17P	Request for examination filed	Effective date: 20210401
2021-07-14	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2021-12-08	DAV	Request for validation of the european patent (deleted)
2021-12-08	DAX	Request for extension of the european patent (deleted)
2022-04-22	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 40058183 Country of ref document: HK
2022-06-01	A4	Supplementary search report drawn up and despatched	Effective date: 20220503
2022-06-01	RIC1	Information provided on ipc code assigned before grant	Ipc: A61P 35/00 20060101ALI20220426BHEP Ipc: A61K 31/4439 20060101ALI20220426BHEP Ipc: A61K 31/4412 20060101ALI20220426BHEP Ipc: A61K 31/435 20060101ALI20220426BHEP Ipc: C07D 403/14 20060101ALI20220426BHEP Ipc: C07D 401/14 20060101AFI20220426BHEP
2024-03-08	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2024-04-10	17Q	First examination report despatched	Effective date: 20240311